摘要
目的 通过比较难治性癫痫（IE患者脑内致痫灶、灶旁组织的药物浓度的差异，促进阐明IE的耐药机制。方法 收集自2007年4月~2009年3月在首都医科大学宣武医院功能神经外科行“致痫灶切除术”的IE患者。用高效液相色谱法（HPLC测定脑组织致痫灶和灶旁组织药物浓度，比较其差异。所有患者均在术前获得知情同意。结果 ①共收集到23例患者的脑组织，分别服用苯巴比妥（PB、苯妥英钠（PHT、卡马西平（CBZ和拉莫三嗪（LTG，将致痫灶和灶旁组织用电生理的方法进行分离，用于脑组织药物浓度的测定。剔除3例，剩余20例，包括PB 4例，CBZ 16例。②20例患者脑组织致痫灶的平均药物浓度为（1.83±0.39μg·mL-1，灶旁组织的平均药物浓度为（2.11±0.45μg·mL-1，采用配对t检验的方法，P=0.000＜0.05，结果有统计学差异，致痫灶的药物浓度低于灶旁组织。分别观察PB组与CBZ组的结果，得出一致性结论。结论 本试验的前续研究已经证实P糖蛋白（P-gp在脑组织的致痫灶中比灶旁组织表达量多，且本试验所选药物均是P-gp的底物，在P-gp表达产物外排泵的作用下，使致痫灶中的药物浓度低于灶旁组织，导致了患者的耐药。
Abstract
OBJECTIVE To clarify the mechanism of drug resistance by comparing the antiepileptic drug concentration in epileptic foci and lesion adjacent tissue. METHODS Patients diagnosed with intractable epilepsy and underwent excision operation of epileptic foci in functional neurosurgery of Xuanwu Hospital of Capital Medical University were collected from April 2007 to March 2009. The drug concentration in the intractable epileptic patients was determined by high performance liquid chromatography. All patients provided informed consent before surgery. RESULTS Twenty-three cases who took phenobarbital(PB，phenytoin(PHT，carbamazepine(CBZ or lamotrigine(LTG before surgery， were collected. All epileptic foci and lesion adjacent tissues were distinguished by nerve electrophysiological method， and used for drug concentration determination. Three cases were excluded. The remaining cases included 4 cases of PB and 16 cases of CBZ. There were 20 patients in this study. The average drug concentration in epileptic foci was （1.83±0.39μg·mL-1. The average drug concentration in lesion adjacent tissue was （2.11±0.45μg·mL-1， SPSS statistical analysis result was statistically significant. The drug concentrations in epileptic foci tissue were lower than that in the lesion. The same results were shown in groups of PB and CBZ. CONCLUSION Previous study has showed that P-gp expression in epileptic foci is significantly higher than that in lesion adjacent tissue. All the drugs included in this study （PB，CBZ，PHT and LTGare substrates of P-gp. We conclude that the higher expression of P-gp in epileptic foci results in lower drug concentration than that in lesion adjacent tissue.
关键词
难治性癫痫 /
脑组织 /
药物浓度 /
高效液相色谱 /
耐药机制
{{custom_keyword}} /
Key words
intractable epilepsy /
brain tissue /
drug concentration /
HPLC /
drug-resistance mechanism
{{custom_keyword}} /
沈江华 姜德春 王育琴.
难治性癫痫患者脑组织致痫灶与灶旁组织药物浓度的比较研究[J]. 中国药学杂志, 2011, 46(10): 774-777
SHEN Jing-hu;JING De-chun;WNG Yu-qin.
Comparative Study on Concentrations of Antiepileptic Drugs in Epileptogenic Focus and Adjacent Tissue in Patients with Intractable Epilepsy[J]. Chinese Pharmaceutical Journal, 2011, 46(10): 774-777
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] ZHU Q， YUAN X R， SUN Z D. The epidemiological and sociological analysis， current situation and our strategies of the epilepsy [J]. J Shanxi Med Univ (山西医科大学学报 ， 2005， 7(2：217-220.
[2] KWAN P， BRODIE M J. Refractory epilepsy： a progressive， intractable but preventable condition [J]. Seizure， 2002， 11(2：77-84.
[3] MARRON I M， ARCH I N， CUCULLO L， et al. Vascular and parenchymal mechanisms in multiple drug resistance： a lesson from human epilepsy [J]. Curr Drug Targets， 2003， 4 (4： 297-304.
[4] KIM K B， BARTLETT M G， ANANDA S S，et al. Rapid determination of the synthetic pyrethroid insecticide， deltamethrin， in rat plasma and tissues by HPLC [J]. J Chromatogr B， 2006， 834 (1-2： 141-148.
[5] ICHIKAWA N， NAORA K， HIRANO H. Quantitation of acetazolamide in rat plasma， brain tissue and cerebrospinal fluid by high-performance liquid chromatography [J]. J Pharm Biomed Anal， 1998， 17 (8： 1415-1421.
[6] ESPOSITO1 S， NOVIELLO S， D′ERRICO G， et al. Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients[J]. J Antimicrob Chemother， 2006， 57 (4： 789-792.
[7] A′LVAREZ-CEDRO′N L， SAYALERO M L， LANAO J M. High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues [J]. J Chromatogr A， 1999， 721 (2： 271-278.
[8] PATIL K M， BODHANKAR S L. Simultaneous determination of lamotrigine， phenobarbitone， carbamazepine and phenytoin in human serum by high-performance liquid chromatography [J]. J Pharm Biomed Anal， 2005， 39 (1-2： 181-186.
[9] LI J， JIANG D C， WANG Y Q. Advance on the role of p-glycoprotein in the mechanism of drug-resistance in epilepsy patients [J]. Chin J New Drugs (中国新药杂志， 2008，17(6：446-449.
[10] LEE S A， SPENCER D D， SPENCER S S. Intracranial EEG seizure-onset patterns in neocortical epilepsy [J]. Epilepsia， 2000， 41 (3：297-307.
[11] CARRENO M， LUDERS H O. General principles of presurgical evaluation // HO Luders， YG Comair， eds. Epilepsy surgery[M]. Philadelphia： Lippincott Williams Wilkins， 2001： 185-199.
[12] RAMACHANDRAN V， SHORVON S D. Clues to the genetic influences of drug responsiveness in epilepsy [J]. Epilepsia， 2003， 44（Suppl 1： 33-37.
[13] LOSCHER W. Drug transporters in the epileptic brain [J]. Epilepsia， 2007， 48（Suppl 1： 8-13.
[14] CHINN L W， KROETZ D L. ABCB1 pharmacogenetics： progress， pitfalls， and promise[J]. Clin Pharmacol Ther， 2007，81（2： 265-269.
[15] WEST C L， MEALEY K L. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein[J]. Am J Vet Res， 2007， 68 (10：1106-1110.
[16] BIALECKA M， HNATYSZYN G， BIELICKA-CYMERMAN J， et al. The effect of MDR1 gene polymorphism in the pathogenesis and the treatment of drug-resistant epilepsy[J]. Neurol Neurochir Pol， 2005， 39 (6： 476-481.
[17] POTSCHKA H， VOLK H A， LOSCHER W， et al. Pharmacoresistance and expression of multiple transporter P-glycoprotein in kindled rats [J]. Neuropharmacol Neurotoxicol， 2004， 15 (10：1657-1661.
[18] POTSCHKA H，BALTES S， LOSCHER W， et al. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats [J]. Epilepsy Res， 2004， 58 (2-3：85-91.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(471 KB)
